Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Joseph Ueland"'
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
HCV genotype 6 (GT-6) is found predominantly in East and Southeast Asia. Clinical studies have focused on patients infected with hepatitis C virus (HCV) GT-6a, where high sustained virologic response (SVR) rates to direct-acting antivirals (DAAs) hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca110c1a683b73ca054f3a312e7d765
https://doi.org/10.1128/aac.02205-18
https://doi.org/10.1128/aac.02205-18
Autor:
Zhou Han, Joseph Ueland, Dennis Hernandez, Vincent Vellucci, Brenda DeGray, Sandra Hartman-Neumann, Fiona McPhee, Nannan Zhou
Publikováno v:
Journal of Antimicrobial Chemotherapy. 71:3495-3505
OBJECTIVE Daclatasvir (DCV) is a pan-genotypic non-structural protein 5A (NS5A) inhibitor that is approved for treatment of hepatitis C virus (HCV) genotype (GT)1 and GT3 in the USA and GT1, GT3 and GT4 in Europe. We set out to examine the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793a3e0bde2f9f656492ea4295f27795
https://doi.org/10.1093/jac/dkw336
https://doi.org/10.1093/jac/dkw336
Autor:
Philip D. Yin, Nannan Zhou, Dennis Hernandez, K. Sims, Xiaoyan Yang, Fiona McPhee, Joseph Ueland, Fei Yu
Publikováno v:
The Journal of Infectious Diseases
Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4–infected population for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a96bd6a1911db40c7eeefd14445a5a2
http://europepmc.org/articles/PMC4690147
http://europepmc.org/articles/PMC4690147
Autor:
Xin Huang, Dennis Hernandez, Fiona McPhee, Xuning Wang, Hiroki Ishikawa, Nannan Zhou, Joseph Ueland, Vincent Vellucci, Hiromitsu Kumada, Yoshiyasu Karino, Fei Yu
Publikováno v:
Antiviral therapy. 23(1)
Background Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non-nucleoside NS5B inhibitor) is an approved regimen for hepatitis C virus (HCV) genotype (GT)-1 treatment in Japan. A comprehe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54c2da13ab5546a7ed0be02db9e00891
https://pubmed.ncbi.nlm.nih.gov/28594332
https://pubmed.ncbi.nlm.nih.gov/28594332
Autor:
Dennis Hernandez, Arlene Carifa, Timothy Eley, Robert A. Fridell, Nannan Zhou, Aaron Monikowski, Paul Falk, Fei Yu, Chunfu Wang, Fiona McPhee, David F. Gardiner, Joseph Ueland
Publikováno v:
Hepatology. 58:902-911
In a sentinel cohort, hepatitis C virus (HCV) patients (primarily genotype [GT] 1a) were treated with daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor). Preexistence, emergence, and persistence of resistance variants in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b455879e98f3cbdffc5838b07ead987b
https://doi.org/10.1002/hep.26388
https://doi.org/10.1002/hep.26388
Publikováno v:
Journal of Clinical Virology. 57:13-18
Background Hepatitis C virus (HCV) NS5A replication complex inhibitors (RCIs) have been shown to exhibit picomolar antiviral activity against genotype 1 (GT1) in vitro. This has translated into rapid and robust declines in HCV RNA in GT1 patients. Le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c0cb2a79fdb6ffba286259492e648d
https://doi.org/10.1016/j.jcv.2012.12.020
https://doi.org/10.1016/j.jcv.2012.12.020
Autor:
Kazuaki Chayama, Joji Toyota, Nannan Zhou, Dennis Hernandez, Eric Hughes, Norifumi Kawada, Hiromitsu Kumada, Hideaki Watanabe, Aaron Monikowski, Hiroki Ishikawa, Fiona McPhee, Osamu Yokosuka, Joseph Ueland, Fei Yu, Yukio Osaki, Namiki Izumi
Publikováno v:
Antiviral therapy. 19(5)
Background Daclatasvir (DCV; BMS-790052) is a picomolar inhibitor of HCV non-structural protein 5A (NS5A) and has demonstrated efficacy in patients chronically infected with HCV. Methods In the double-blind, randomized studies AI444021 and AI444022,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fdcf241618372500b1d7491bb875101
https://pubmed.ncbi.nlm.nih.gov/24448487
https://pubmed.ncbi.nlm.nih.gov/24448487
Publikováno v:
Journal of Clinical Virology. 77:115
The authors regret there is an error in Fig. 3 of their paper. Please find below the new version of Fig. 3. As a result of this correction, the statement in the Results Section 4 should read as below: The NS5A-L31 residue is highly conserved in GT1a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21b50d3516b52d7d0385059bd78e1f06
https://doi.org/10.1016/j.jcv.2016.02.008
https://doi.org/10.1016/j.jcv.2016.02.008